The Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is expanding as awareness of this rare autoimmune neurological disorder continues to increase. Chronic inflammatory demyelinating polyneuropathy (CIDP) causes nerve damage, weakness, and sensory loss due to immune-mediated damage to peripheral nerves. The market reached a value of USD 4.41 Billion in 2025 and is projected to grow at a CAGR of 6.90% between 2026 and 2035, reaching approximately USD 8.59 Billion by 2035. Growth is primarily driven by improved diagnosis, increasing availability of advanced therapies, and ongoing investments in neurological research.

What Is the Current Size and Share of the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market?

The Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market size and share are dominated by immunotherapy-based treatments and supportive neurological care. Intravenous immunoglobulin (IVIG) currently holds a significant market share due to its effectiveness in reducing inflammation and improving nerve function. Other commonly used treatments include corticosteroids, plasma exchange, stem cell transplant, physical therapy, and additional supportive therapies. Hospitals and specialty neurological clinics represent the largest end-user segments because they offer advanced diagnostic and treatment facilities required for managing CIDP.

How Is the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Segmented?

The Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is segmented based on therapeutic method, diagnosis, route of administration, end user, and region. Therapeutic methods include corticosteroids, intravenous immunoglobulin, plasma exchange, immunotherapy, stem cell transplant, physical therapy, and others. Diagnostic techniques involve electrodiagnostic testing, nerve conduction studies, electromyography, spinal fluid analysis, and other methods. By route of administration, the market includes intravenous, oral, and other delivery methods. Major end users include hospitals, specialty neurological clinics, and research and academic laboratories.

Request sample report Explore

Which Regions and Companies Are Leading the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market?

The Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market growth is strongest in North America and Europe, where advanced healthcare systems and higher awareness levels support early diagnosis and treatment. The Asia Pacific region is also emerging as a significant market due to expanding healthcare infrastructure and increasing neurological research. Key companies operating in the market include Grifols, S.A., Octapharma AG, Baxter International Inc., Pfizer Inc., CSL Behring LLC, MedDay SA, Shire plc, Takeda Pharmaceutical Company Limited, Teijin Limited, and Momenta Pharmaceuticals, Inc. These companies are actively focusing on research, product innovation, and strategic collaborations to strengthen their global presence.